GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Ipsen SA (OTCPK:IPSEY) » Definitions » Price-to-Owner-Earnings
中文

Ipsen (IPSEY) Price-to-Owner-Earnings : 13.39 (As of Apr. 24, 2024)


View and export this data going back to 2007. Start your Free Trial

What is Ipsen Price-to-Owner-Earnings?

As of today (2024-04-24), Ipsen's share price is $30.54. Ipsen's Owner Earnings per Share (TTM) ended in Dec. 2023 was $2.28. It's Price-to-Owner-Earnings for today is 13.39.


The historical rank and industry rank for Ipsen's Price-to-Owner-Earnings or its related term are showing as below:

IPSEY' s Price-to-Owner-Earnings Range Over the Past 10 Years
Min: 8.27   Med: 26.49   Max: 65.64
Current: 13.49

During the past 13 years, the highest Price-to-Owner-Earnings of Ipsen was 65.64. The lowest was 8.27. And the median was 26.49.


IPSEY's Price-to-Owner-Earnings is ranked better than
79.91% of 423 companies
in the Drug Manufacturers industry
Industry Median: 27.58 vs IPSEY: 13.49

As of today (2024-04-24), Ipsen's share price is $30.54. Ipsen's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was $2.10. Therefore, Ipsen's PE Ratio for today is 14.52.

As of today (2024-04-24), Ipsen's share price is $30.54. Ipsen's EPS without NRI for the trailing twelve months (TTM) ended in was $2.49. Therefore, Ipsen's PE Ratio without NRI for today is 12.28.

During the past 13 years, Ipsen's highest PE Ratio without NRI was 2453.57. The lowest was 5.96. And the median was 17.26.


Ipsen Price-to-Owner-Earnings Historical Data

The historical data trend for Ipsen's Price-to-Owner-Earnings can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Ipsen Price-to-Owner-Earnings Chart

Ipsen Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Price-to-Owner-Earnings
Get a 7-Day Free Trial Premium Member Only Premium Member Only - 13.36 8.26 10.07 12.65

Ipsen Semi-Annual Data
Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Price-to-Owner-Earnings Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 8.26 - 10.07 - 12.65

Competitive Comparison of Ipsen's Price-to-Owner-Earnings

For the Drug Manufacturers - Specialty & Generic subindustry, Ipsen's Price-to-Owner-Earnings, along with its competitors' market caps and Price-to-Owner-Earnings data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Ipsen's Price-to-Owner-Earnings Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Ipsen's Price-to-Owner-Earnings distribution charts can be found below:

* The bar in red indicates where Ipsen's Price-to-Owner-Earnings falls into.



Ipsen Price-to-Owner-Earnings Calculation

In 1986 Berkshire Hathaway Shareholder Letter, Warren Buffett defined owner earnings as follows:

"These represent (a) reported earnings plus (b) depreciation, depletion, amortization, and certain other non-cash charges...less (c) the average annual amount of capitalized expenditures for plant and equipment, etc. that the business requires to fully maintain its long-term competitive position and its unit volume. (If the business requires additional working capital to maintain its competitive position and unit volume, the increment also should be included in (c))...Our owner-earnings equation does not yield the deceptively precise figures provided by GAAP, since (c) must be a guess - and one sometimes very difficult to make. Despite this problem, we consider the owner earnings figure, not the GAAP figure, to be the relevant item for valuation purposes - both for investors in buying stocks and for managers in buying entire businesses...All of this points up the absurdity of the 'cash flow' numbers that are often set forth in Wall Street reports. These numbers routinely include (a) plus (b) - but do not subtract (c)."

Ipsen's Price-to-Owner-Earnings for today is calculated as

Price-to-Owner-Earnings=Share Price/Owner Earnings per Share (TTM)
=30.54/2.28
=13.39

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Ipsen  (OTCPK:IPSEY) Price-to-Owner-Earnings Explanation

For how to get Owner Earnings per Share (TTM), please click.


Ipsen Price-to-Owner-Earnings Related Terms

Thank you for viewing the detailed overview of Ipsen's Price-to-Owner-Earnings provided by GuruFocus.com. Please click on the following links to see related term pages.


Ipsen (IPSEY) Business Description

Traded in Other Exchanges
Address
65 Quai Georges Gorse, Billancourt Cedex, Boulogne, FRA, 92100
Ipsen is a global biotechnology company headquartered in France that develops and commercializes medicines across three therapeutic areas: oncology, neuroscience, and rare diseases. Ipsen was founded in 1929 as a consumer healthcare company focused on prescription-based products for digestive disorders and neurological disorders. Over the past nearly 100 years, Ipsen has shifted its focus to specialty care, which comprises the vast majority of its total revenue. In February 2022, Ipsen announced the divestment of its consumer healthcare business, which accounted for 8% of 2021 revenue. Ipsen has a large global footprint and sells more than 25 drugs in 115 countries.